US Patent 8,039,627: Valbenazine Claim Scope, Expiration, Orange Book Status, and Generic Risk
US Patent 8,039,627 protects valbenazine, the active pharmaceutical ingredient in Ingrezza, as a specifically defined stereochemical compound and as a pharmaceutical composition. The patent is a composition-of-matter patent, not a method-of-use patent. Its principal commercial value is the claim to the valbenazine molecule itself, including pharmaceutically acceptable salts.
The patent does not, based on the supplied claims, separately protect a dosing regimen, tardive dyskinesia treatment method, capsule formulation, manufacturing process, polymorph, or specific indication.
What drug does US Patent 8,039,627 protect?
The compound in claim 1 is valbenazine, also known as NBI-98854. Valbenazine is a vesicular monoamine transporter 2 inhibitor approved by the FDA under the brand name Ingrezza for tardive dyskinesia and chorea associated with Huntington's disease.[1]
The claimed molecule is the valine ester of a tetrabenazine-related benzoquinolizine compound. Its structure includes:
| Structural element |
Claim significance |
| (S)-2-amino-3-methylbutyric acid |
The valine portion of valbenazine |
| (2R,3R,11bR) stereochemistry |
Limits the claim to one defined stereochemical configuration |
| 3-isobutyl substituent |
Defines the hydrophobic side chain |
| 9,10-dimethoxy substitution |
Defines the aromatic substitution pattern |
| Pyrido[2,1-a]isoquinoline core |
Defines the fused bicyclic scaffold |
| Ester linkage |
Distinguishes valbenazine from the parent alcohol or ketone compounds |
| Pharmaceutically acceptable salt |
Extends coverage beyond the neutral free compound |
The commercial active ingredient is generally supplied as valbenazine tosylate, although the patent claim is broader than one named salt because it covers the claimed compound and pharmaceutically acceptable salts generally.
What does claim 1 of US 8,039,627 cover?
Claim 1 is a product claim covering:
(S)-2-amino-3-methylbutyric acid (2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-yl ester, or a pharmaceutically acceptable salt thereof.
This is a narrow but commercially important composition-of-matter claim.
Stereochemical scope
The claim requires the stated S and R configurations. A compound with a different configuration at any of the specified stereocenters would not literally meet the claim. The claim therefore excludes:
- The opposite valine enantiomer.
- Diastereomers at the 2, 3, or 11b positions.
- Racemic mixtures, unless the mixture otherwise falls within the claim under an applicable infringement theory.
- A different stereoisomer of the tetrabenazine-derived portion.
Stereochemistry is a major enforcement feature. A generic manufacturer would normally need to demonstrate that its active ingredient has the same stereochemical configuration or establish a non-infringement position based on a materially different structure.
Salt coverage
The phrase "or a pharmaceutically acceptable salt thereof" extends claim 1 to salts formed with pharmaceutically acceptable acids or bases. The scope generally can include different salt forms of the same claimed active moiety, subject to claim construction and the technical requirements for a pharmaceutically acceptable salt.
The salt language does not automatically cover:
- A different chemical derivative.
- A prodrug with a changed covalent structure.
- A different ester.
- A solvate that is not also a claimed salt.
- A polymorph unless the polymorph is part of the claimed salt or compound and otherwise falls within the claim.
The claim is therefore broad across salt selection but narrow across covalent structure and stereochemistry.
What claim 1 does not cover
Claim 1 does not expressly recite:
- A particular dosage strength.
- A tablet, capsule, or oral solution.
- A specific excipient.
- A release profile.
- A treatment indication.
- A dosing frequency.
- A manufacturing method.
- A crystal form.
- A particle-size distribution.
- A purity threshold.
- A pharmaceutical package or labeling regime.
A competitor could not avoid claim 1 merely by changing the capsule shell, excipient, dose, or labeling if it still makes, uses, offers for sale, or sells the claimed valbenazine compound or a covered salt.
What does claim 2 of US 8,039,627 cover?
Claim 2 covers:
A pharmaceutical composition comprising a compound according to claim 1 and a pharmaceutically acceptable carrier or diluent.
Claim 2 is dependent on claim 1. It therefore inherits all of claim 1's limitations, including the exact chemical structure, stereochemistry, ester configuration, and salt coverage.
The claim reaches compositions containing the claimed compound together with a pharmaceutically acceptable carrier or diluent. It is not limited to a particular:
- Route of administration.
- Dosage form.
- Carrier.
- Diluent.
- Concentration.
- Ratio of active ingredient to excipient.
- Disease indication.
The term "comprising" is open-ended. A composition containing the claimed valbenazine compound, a carrier or diluent, and additional ingredients may still fall within the claim.
Formulation protection under claim 2
Claim 2 provides a basic formulation claim, but it is not a detailed formulation patent. It may cover an Ingrezza capsule composition if the product contains the claimed valbenazine compound and a pharmaceutically acceptable carrier or diluent.
It does not expressly require or protect:
- A specific capsule composition.
- A particular coating.
- A controlled-release system.
- A defined dissolution profile.
- A particular excipient combination.
- A specific manufacturing process.
Later formulation patents, if valid and listed for the product, could provide more targeted protection around dosage forms, stability, particle engineering, salt forms, or manufacturing controls. Those protections are separate from the two claims supplied here.
How strong is the patent estate under US 8,039,627?
The patent has strong claim-type value because claim 1 is directed to the active pharmaceutical ingredient rather than only to a use or formulation.
| Factor |
Assessment |
| Claim category |
Composition of matter |
| Commercial relevance |
High because the claim covers valbenazine itself |
| Structural breadth |
Narrow |
| Stereochemical breadth |
Narrow |
| Salt breadth |
Relatively broad |
| Formulation breadth |
Moderate through claim 2 |
| Method-of-use protection |
None in the supplied claims |
| Manufacturing protection |
None in the supplied claims |
| Design-around difficulty |
Potentially high for a generic seeking the same active ingredient |
| Vulnerability |
Depends on validity challenges involving novelty, obviousness, written description, enablement, and claim construction |
A composition-of-matter claim can block an ordinary generic even when the generic uses a different excipient system, capsule supplier, manufacturing site, or labeling strategy. A formulation change would generally not avoid claim 1 if the generic still uses valbenazine.
The narrow structure also creates potential validity and non-infringement issues. Relevant legal questions would include whether the claimed stereoisomer was disclosed or rendered obvious by tetrabenazine and related prior art, whether the specification adequately supports the claimed stereochemical compound and salts, and whether an accused product has the claimed configuration.
When does US Patent 8,039,627 lose exclusivity?
The patent's term is generally expected to run into 2027 based on its U.S. patent-term framework and publicly associated Orange Book information. The exact enforceable expiration date must be determined from the patent's continuity data, patent-term adjustment, any terminal disclaimer, and any applicable patent-term extension.
| Exclusivity layer |
Relevance to valbenazine |
| Patent exclusivity |
The 8,039,627 composition-of-matter patent is the principal protection identified by the supplied claims |
| FDA new chemical entity exclusivity |
Valbenazine received FDA approval in 2017 and benefited from the five-year NCE period applicable to an eligible new active ingredient |
| Pediatric exclusivity |
Any six-month pediatric extension would depend on FDA-recognized pediatric study completion and the applicable listed patents |
| Orange Book listed patents |
Relevant to ANDA certification and potential 30-month litigation stays |
| Regulatory exclusivity after patent expiry |
No automatic permanent barrier remains after patent and statutory exclusivity periods end |
FDA approved Ingrezza on April 11, 2017.[1] A five-year NCE period would generally have prevented submission of an ANDA relying on the valbenazine approval before April 2022, subject to the specific statutory rules governing submission and certification. Patent protection can continue beyond NCE exclusivity.
What is the Orange Book status of valbenazine?
Valbenazine is an FDA-approved small-molecule drug, not a biologic. Generic applicants would therefore use the abbreviated new drug application pathway rather than the biosimilar pathway.
The Orange Book is relevant because it identifies patents submitted by the NDA holder or sponsor for the approved drug. For an ANDA applicant, an Orange Book-listed patent can generate a certification obligation:
- Paragraph I: No patent information has been submitted.
- Paragraph II: The patent has expired.
- Paragraph III: The applicant will wait until patent expiration.
- Paragraph IV: The patent is invalid, unenforceable, or will not be infringed.
A Paragraph IV notice can lead to patent litigation and, if timely suit is filed, a statutory stay of FDA approval for up to 30 months under the Hatch-Waxman framework.[2]
The supplied claims alone do not establish the complete current Orange Book listing for Ingrezza. They establish that US 8,039,627 has the type of claims that could support an Orange Book listing: a claim directed to the active ingredient and a pharmaceutical composition containing it.
Are there Paragraph IV challenges to valbenazine?
A Paragraph IV analysis requires current FDA Orange Book data, ANDA certifications, notice letters, and court dockets. The existence of US 8,039,627 by itself does not prove that a particular generic company has filed a Paragraph IV certification.
For a generic valbenazine applicant, the principal legal theories would likely involve:
- Non-infringement based on stereochemical or salt differences.
- Invalidity based on anticipation.
- Obviousness based on tetrabenazine, valbenazine-related compounds, and prior medicinal-chemistry disclosures.
- Lack of written description or enablement for the full salt scope.
- Expiration or unenforceability.
- A challenge to later formulation or method patents separately from the compound patent.
A generic that uses the same valbenazine active ingredient would face materially greater risk under claim 1 than a generic that uses a different active compound. A different formulation alone would generally be insufficient to avoid the composition-of-matter claim.
Does valbenazine face biosimilar risk?
No. Valbenazine is a chemically synthesized small molecule. The relevant competitive pathway is a generic ANDA, not a biosimilar application under the Public Health Service Act.
The principal post-exclusivity risk is therefore generic substitution after the relevant patents and regulatory exclusivities no longer block approval. Biosimilar concepts such as interchangeability, reference-product exclusivity under the biologics statute, and patent dance procedures do not apply to Ingrezza.
What patent litigation affects valbenazine?
The critical litigation questions are:
- Whether US 8,039,627 remains enforceable at the time of a generic launch.
- Whether the NDA holder has listed additional patents covering valbenazine formulations, methods of use, salts, or manufacturing.
- Whether an ANDA filer has delivered a Paragraph IV notice.
- Whether a lawsuit was filed within 45 days of notice.
- Whether a 30-month stay applies.
- Whether any settlement permits an agreed launch date before patent expiry.
- Whether later patents are invalidated, narrowed, or dismissed.
The supplied claims do not contain a method-of-use limitation. They therefore do not directly claim treatment of tardive dyskinesia or Huntington's disease. Such protection would have to arise from separate patents or regulatory exclusivity.
What generic launch scenarios exist?
Launch after patent expiry
This is the lowest litigation-risk scenario if no later blocking patent remains enforceable. An ANDA applicant could seek approval and launch after expiration of the relevant composition-of-matter patent and any applicable pediatric extension.
At-risk launch
A generic company could launch before final resolution of litigation if it believes the patent is invalid, unenforceable, or not infringed. This creates damages exposure and potential injunctive relief.
Launch after settlement
The NDA holder and generic applicant could agree to a future launch date or other terms, subject to antitrust and Hatch-Waxman considerations. The supplied claims provide no evidence of a settlement.
Formulation-only design-around
Changing excipients or the dosage form would not normally avoid claim 1 if the same valbenazine compound is used. It could matter only for separate formulation claims.
How does US 8,039,627 compare with method-of-use and formulation patents?
| Patent type |
What it protects |
Relevance to Ingrezza |
| Composition of matter |
The active molecule or salt |
Highest generic blocking value |
| Pharmaceutical composition |
Active ingredient plus carrier or diluent |
Supports product-level protection but inherits compound limitations |
| Method of use |
Treatment of a disease or symptom |
Can affect skinny-label and induced-infringement issues |
| Formulation |
Specific dosage form, release profile, excipient system, or stability profile |
Can create additional barriers after compound claims are challenged |
| Manufacturing process |
Synthesis, purification, crystallization, or salt formation |
May restrict suppliers but often has narrower enforcement scope |
| Polymorph or solid form |
Specific crystalline or amorphous form |
Can create product-specific infringement issues |
US 8,039,627 is strongest as a compound patent. Its claim 2 formulation coverage is functional and broad in wording but limited by claim 1's narrow molecule.
Key Takeaways
- US 8,039,627 claims valbenazine, the active ingredient in Ingrezza.
- Claim 1 is a composition-of-matter claim covering one defined stereoisomer and pharmaceutically acceptable salts.
- Claim 2 covers pharmaceutical compositions containing the claimed compound and a pharmaceutically acceptable carrier or diluent.
- The supplied claims do not cover a specific indication, dosing regimen, formulation technology, polymorph, or manufacturing process.
- The patent is commercially stronger than a standalone method-of-use patent because a generic using valbenazine would face the compound claim regardless of excipients or labeling.
- Valbenazine is subject to generic, not biosimilar, competition.
- FDA approval occurred on April 11, 2017, and the five-year NCE exclusivity period would generally have ended in 2022.
- The patent's expected term reaches into 2027, subject to the official patent-term calculation and any applicable adjustment or extension.
- A complete Paragraph IV, Orange Book, litigation, and settlement analysis requires the current FDA and court records beyond the two supplied claims.
FAQs
What is US Patent 8,039,627 commonly associated with?
It is associated with valbenazine, marketed by Neurocrine Biosciences as Ingrezza.
Does US 8,039,627 cover tetrabenazine?
No. The supplied claim is directed to valbenazine, a specific valine ester with defined stereochemistry. Tetrabenazine is a different compound.
Can a generic avoid US 8,039,627 by using a different valbenazine salt?
Not necessarily. Claim 1 expressly includes pharmaceutically acceptable salts. A different salt may still fall within the claim.
Does a different capsule or excipient avoid the patent?
Generally no, if the product contains the claimed valbenazine compound or a covered salt. Claim 1 is independent of the dosage form and excipient system.
Is US 8,039,627 a patent for treating tardive dyskinesia?
Not based on the supplied claims. The claims cover the compound and a composition containing it. Treatment-method protection would require separate claims.
References
- U.S. Food and Drug Administration. (2017). FDA approves new drug to treat tardive dyskinesia. https://www.fda.gov
- U.S. Congress. (1984). Drug Price Competition and Patent Term Restoration Act of 1984, 21 U.S.C. ยง 355(j).
- U.S. Patent and Trademark Office. (2011). United States Patent No. 8,039,627.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/index.cfm
